Arvinas (ARVN)
(Delayed Data from NSDQ)
$25.63 USD
+0.03 (0.12%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $25.66 +0.03 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Arvinas, Inc. [ARVN]
Reports for Purchase
Showing records 1 - 20 ( 213 total )
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
VERITAC-2 Designed to Maximize Vepdeg?s Efficacy - Our Thoughts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -ASCO 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Vepdeg Palbo Combo Continues to be Promising with Consistent CBR Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Updated CDK4/6i Combo Data; Vepdeg Continues to Show Backbone Potential
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Continue to View Vepdeg?s Potential as a Combination Therapy Constructively
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; VERITAC-2 Top Line Data on Track for 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- ASCO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ASCO 2024 Abstract Titles for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Novartis Deal Validates Arvinas? Pipeline Reprioritization; PT Down to $87
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
ARVN Out-Licenses ARV-766 to NVS; Maintains Sharp Focus
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
AACR 2024 Abstract Roundup for Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Arvinas Enters the Neurodegeneration Space With LRRK2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Company: Arvinas, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Busy Year of Execution Across Pipeline, LRRK2 Enters Clinic
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R